American Journal of Preventive Medicine
Tobacco product regulationFederal Approaches to the Regulation of Noncigarette Tobacco Products
Section snippets
Context
In 2009, President Obama signed into law the Family Smoking Prevention and Tobacco Control Act1 (TCA)—far-reaching legislation giving the Food and Drug Administration (FDA) the authority to regulate tobacco products. In his signing statement, the President stated that “the decades-long effort to protect our children from the harmful effects of tobacco has emerged victorious.”2 Yet, despite this optimism, tobacco remains the leading cause of preventable death in the U.S.3
At least in part,
Evidence Acquisition
During the years 2010–2011, standard legal research techniques were used to identify and compile relevant statutes, regulations, decisions, pleadings, proposals, and related materials. Sources included standard commercial legal databases such as LexisNexis and Westlaw, online sources for pending rules and legislation, and direct contact with courts for legal pleadings and unpublished decisions. These legal authorities related to many aspects of the regulation of other tobacco products,
Evidence Synthesis
Research during the years 2010–2011 revealed that the federal regulation of these other products lags behind the regulation of more “traditional” tobacco products, such as cigarettes and moist snuff. Federal regulatory options to expand regulation of these products were identified.
Category Prohibition
The first regulatory option available to the FDA is perhaps the most dramatic. The FDA has the authority to issue tobacco product standards which it determines would protect public health.21 These standards could include the prohibition of entire classes of tobacco products with certain exceptions, including all cigarettes, all smokeless tobacco products, all little cigars, and all pipe tobacco.22
Moreover, the FDA has the authority to require premarket review for products that are not
Summary
Because many tobacco products are not currently regulated in the same manner as cigarettes, there is a need to consider new federal regulation of the products. This regulation could take many forms: prohibiting an entire category of tobacco products; price regulation, including regulations related to free samples, coupons, and minimum pack size; a prohibition on characterizing flavors; expanded warning labels, potentially including graphic warnings; a prohibition on health descriptors; and
References (56)
- et al.
Waterpipe (hookah) tobacco smoking among youth
Curr Probl Pediatr Adolesc Health Care
(2011) - et al.
Minors' access to single cigarettes in California
Prev Med
(1998) - et al.
Text and graphic warnings on cigarette packages: findings from the international tobacco control four country study
Am J Prev Med
(2007) Family Smoking Prevention and Tobacco Control Act, 21 U.S.C.A. §§ 387–387u (West 2009); Pub. L. No. 111-31, 123 Stat. 1776 (2009); 21 C.F.R. §§ 1140.30, 1140.32 (2010)
Smoking-attributable mortality, years of potential life lost, and productivity losses—U.S., 2000–2004
MMWR Morb Mortal Wkly Rep
(2008)- 21 U.S.C. § 387a(b)...
- 21 C.F.R. § 1140...
- 21 U.S.C. § 387g(a)(1)(A)...
- et al.
State and local policy as a tool to complement and supplement the FDA law
Hastings Sci Technol Law J
(2010)
Unintentional child poisonings through ingestion of conventional and novel tobacco products
Pediatrics
Electronic nicotine delivery systems: is there a need for regulation?
Tob Control
“A whole 'nother smoke” or a cigarette in disguise: how RJ Reynolds reframed the image of little cigars
Am J Public Health
Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA
Tob Control
Virginia tobacco maker seeks new FDA designation
Fox News
Star Scientific's tobacco lozenges get favorable FDA ruling
Bloomberg
Regulation of e-cigarettes and other tobacco products, letter to stakeholders
Flavored tobacco pellets are denounced as a lure to young users
New York Times
Cited by (22)
Method development and validation of dissolution testing for nicotine release from smokeless tobacco products using flow-through cell apparatus and UPLC-PDA
2020, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesClaims in vapour device (e-cigarette) regulation: A Narrative Policy Framework analysis
2017, International Journal of Drug PolicyCitation Excerpt :A 2015 national survey of students reported that 16.0% of high school and 5.3% of middle school students had used a vapour device in the past 30 days (Singh et al., 2016). It appears that no vapour devices were marketed in the US prior to February 15, 2007 (Freiberg, 2012). From 2008 to 2010, the Food and Drug Administration (FDA) attempted to regulate vapour devices as an unapproved medical drug/device (US Food and Drug Aministration, 2011, April 25) and took steps to interdict their importation and distribution (Washington Legal Foundation, 2010, July 21).
Overview of Electronic Nicotine Delivery Systems: A Systematic Review
2017, American Journal of Preventive MedicineCitation Excerpt :Reviews have been published on ENDS in general10–21 or on specific topics, including health effects22–58; impact on smoking cessation29,40–43,45,47,48,51,59–73; product features22,39,41–43,45,47,74–77; potential to induce dependence28,45,47,78,79; consumer perceptions26,48,80,81; patterns of use8,26,43,48,51,82–90; and policies.8,48,91–98 Two conducted a bibliometric review of the ENDS literature86,99 and 46% of the reviews were systematic.11,13,15,16,22–28,33,34,36,39,46,48,53–58,60,61,66,68,70–75,79–82,85,86,88–90,93,97,100–104 The dramatically changing product landscape warrants frequent updates and synthesis of the rapidly growing evidence to inform prudent practice, policy, and regulation.9,105,106
Trends in medical malpractice claims in patients with cleft or craniofacial abnormalities in the United States
2016, International Journal of Pediatric OtorhinolaryngologyCitation Excerpt :However, this commercial and computerized database does not suffer from the geographic and socioeconomic homogeneity limitations inherent to using private insurer closed claims databases. In addition, WestLawNext and its predecessor, WestLaw, have previously been used in studies ranging across many fields of study and thus were deemed acceptable for use [13–15,32–43]. International organizations have cited healthcare cost analysis as a research priority in patients with craniofacial abnormalities and thus our research contributes to this mandate [7,44].
Patterns of alternative tobacco product use: Emergence of hookah and E-cigarettes as preferred products amongst youth
2016, Journal of Adolescent HealthCitation Excerpt :Furthermore, our results also indicate that another group of teens, overrepresented by boys, may benefit from interventions targeting all types of tobacco products. Current regulations related to tobacco products do not meaningfully impact three of the five products examined in this study (cigars, e-cigarettes, and hookah) [26]. The regulation of flavoring, youth access, and secondhand exposure are topics that should continue to receive careful consideration.
Trends in cigarette, cigar, and smokeless tobacco use among New York City public high school youth smokers, 2001-2013
2015, Preventive Medicine ReportsCitation Excerpt :Ultimately, these data emphasize the need for public health efforts focus on consumption of other tobacco products, such as cigars and smokeless tobacco (Freiberg, 2012). To address this issue, in August 2014, NYC introduced a policy equalizing the price of little cigars to that of cigarettes, making it more difficult for youth to gain access to these products (Freiberg, 2012; The New York State Department of Taxation and Finance, 2014). Future studies will be needed to assess the impact of such legislation.